Hackensack University Medical Center Participating in Clinical Trial for Investigational Alzheimer’s Disease Medication

Experimental Drug May Lead to Rapid Recovery of Memory and Function

The physicians at Hackensack University Medical Center and the Center for Memory Loss & Brain Health are conducting a clinical trial that may have big implications for patients and families impacted by Alzheimer’s disease. Investigators have started enrollment in a clinical trial for ATH-1017, an investigational medication for the treatment of mild to moderate Alzheimer’s disease.

According to clinical trial sponsor Athira Pharma, ATH-1017 enhances the HGF/MET system, one of the brain’s repair mechanisms. Enhancing HGF/MET signaling may improve brain activity, repair brain connections, reduce stress and inflammation, and rescue brain cells, which may lead to rapid recovery of memory and function.

“ATH-1017 offers hope for patients and loved ones affected by Alzheimer’s disease, as well as for the future of dementia care,” said Manisha Parulekar, M.D., AGSF, FACP, Co-Director of the Center and Division Chief, Geriatrics, Hackensack University Medical Center and Associate Professor of Internal Medicine, Hackensack Meridian School of Medicine. “This medication is delivered through a daily injection and may have the potential to alter the course of Alzheimer’s disease.”

“ATH-1017 is an investigational drug designed to support the growth and survival of nerve cells,” said Florian Thomas, M.D., Ph.D., Co-Director of the Center and Professor and Founding Chair, Department of Neurology, Hackensack University Medical Center and Hackensack Meridian School of Medicine. “This study will determine the safety and effectiveness of ATH-1017 to improve cognition in people with mild to moderate Alzheimer’s disease.”
“With the number of New Jersey residents living with Alzheimer’s disease projected to rise in the coming years, we are proud to provide older adults in our communities with access to this pioneering ATH-1017 clinical trial,” said Mark Sparta, FACHE, president and chief hospital executive, Hackensack University Medical Center. “Participating in groundbreaking research puts us one step closer to finding a cure for Alzheimer’s disease.”